[Assessment of bone quality. Drug developments for restoring bone mass and quality in the treatment of osteoporosis].
To improve bone mass and quality two strategies are currently taken ; one is the indirect stimulation of bone formation through the endogenous parathyroid function augmented by anti-resorptive agents that do not have a direct suppressive effect on the osteoblastic function, and the other is the direct osteoblast stimulation by agents themselves. The former group includes anti-RANKL antibody and cathepsin K inhibitors and the latter has strontium ranelate, teriparatide, and anti-sclerostin antibody. Clinical data of these drugs in osteoporosis are expected.
Nakamura
Toshitaka
T
University of Occupational and Environmental Health, Department of Orthopedics School of Medicine.
D048868:Adaptor Proteins, Signal Transducing; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D050071:Bone Density Conservation Agents; D019485:Bone Morphogenetic Proteins / Q000276:immunology; D001862:Bone Resorption; D056657:Cathepsin K; D002403:Cathepsins / Q000037:antagonists & inhibitors; D015195:Drug Design; D005819:Genetic Markers / Q000276:immunology; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use; D010006:Osteoblasts / Q000502:physiology; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology*; D010280:Parathyroid Glands / Q000502:physiology; D053245:RANK Ligand / Q000276:immunology; D019379:Teriparatide / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use
D048868:Adaptor Proteins, Signal Transducing; D000911:Antibodies, Monoclonal; D050071:Bone Density Conservation Agents; D019485:Bone Morphogenetic Proteins; D005819:Genetic Markers; D009942:Organometallic Compounds; D053245:RANK Ligand; C422903:SOST protein, human; D013876:Thiophenes; C081587:strontium ranelate; D019379:Teriparatide; D002403:Cathepsins; C534130:CTSK protein, human; D056657:Cathepsin K